GTC
TSHA icon

Ghost Tree Capital’s Taysha Gene Therapies TSHA Stock Holding History

Ghost Tree Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.32M Buy
2,150,000
+900,000
+72% +$1.97M 1.31% 29
2024
Q2 		$2.8M Buy
1,250,000
+300,000
+32% +$873K 0.88% 39
2024
Q1 		$2.73M Sell
950,000
-1,150,000
-55% -$2.4M 0.75% 43
2023
Q4 		$3.72M Buy
2,100,000
+775,000
+58% +$1.55M 1.22% 25
2023
Q3 		$4.19M Buy
+1,325,000
New +$2.47M 1.38% 26

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ghost Tree Capital's TSHA Position: Q3 2024 in Review

Ghost Tree Capital increased its Taysha Gene Therapies (TSHA) stake by 72% in Q3 2024, buying an estimated $1.97M and bringing the position to 2,150,000 shares worth $4.32M. The position accounts for 1.31% of the portfolio, ranked #29.

Ghost Tree Capital first reported a position in TSHA in Q3 2023 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • Ghost Tree Capital held 2,150,000 shares of Taysha Gene Therapies worth $4.32M as of Q3 2024.
  • Ghost Tree Capital bought 900,000 Taysha Gene Therapies shares in Q3 2024, an estimated $1.97M.
  • Taysha Gene Therapies made up 1.31% of Ghost Tree Capital's portfolio in Q3 2024, its #29 holding.
  • Ghost Tree Capital first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 5 quarters since.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.